BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20835509)

  • 1. Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America.
    Alvarez C; Salazar R; Galindez J; Rangel F; Castaãeda ML; Lopardo G; Cuhna CA; Roldan Y; Sussman O; Gutierrez G; Cure-Bolt N; Seas C; Carcamo C; Castrillo M
    Braz J Infect Dis; 2010; 14(3):256-63. PubMed ID: 20835509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults.
    Jantarapakde J; Phanuphak N; Chaturawit C; Pengnonyang S; Mathajittiphan P; Takamtha P; Dungjun N; Pinyakorn S; Pima W; Prasithsirikul W; Phanuphak P
    AIDS Patient Care STDS; 2014 Jul; 28(7):331-40. PubMed ID: 24914459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burden of metabolic syndrome among HIV-infected patients in Southern Ethiopia.
    Tesfaye DY; Kinde S; Medhin G; Megerssa YC; Tadewos A; Tadesse E; Shimelis T
    Diabetes Metab Syndr; 2014; 8(2):102-7. PubMed ID: 24907175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of first-line antiretroviral therapy in Latin America: analysis from the LATINA retrospective cohort study.
    Angriman F; Belloso WH; Sierra-Madero J; Sánchez J; Moreira RI; Kovalevski LO; Orellana LC; Cardoso SW; Crabtree-Ramirez B; La Rosa A; Losso MH
    Int J STD AIDS; 2016 Feb; 27(2):118-26. PubMed ID: 25740759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART.
    Cahn P; Leite O; Rosales A; Cabello R; Alvarez CA; Seas C; Carcamo C; Cure-Bolt N; L'Italien GP; Mantilla P; Deibis L; Zala C; Suffert T
    Braz J Infect Dis; 2010; 14(2):158-66. PubMed ID: 20563442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic syndrome in French HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy.
    Biron A; Bobin-Dubigeon C; Volteau C; Piroth L; Perré P; Leport C; Prazuck T; Jovelin T; Billard M; Sébille V; Bard JM; Raffi F; Biron C
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1672-8. PubMed ID: 22731114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What should we know about metabolic syndrome and lipodystrophy in AIDS?
    Signorini DJ; Monteiro MC; Andrade Mde F; Signorini DH; Eyer-Silva Wde A
    Rev Assoc Med Bras (1992); 2012; 58(1):70-5. PubMed ID: 22392319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Prevalence of Metabolic Syndrome and Cardiovascular Disease Risk Among People with HIV on Stable ART in Southwestern Uganda.
    Muyanja D; Muzoora C; Muyingo A; Muyindike W; Siedner MJ
    AIDS Patient Care STDS; 2016 Jan; 30(1):4-10. PubMed ID: 26683587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy.
    Hansen BR; Petersen J; Haugaard SB; Madsbad S; Obel N; Suzuki Y; Andersen O
    HIV Med; 2009 Jul; 10(6):378-87. PubMed ID: 19490178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of metabolic syndrome in HIV-infected patients naive to antiretroviral therapy or receiving a first-line treatment.
    Calza L; Colangeli V; Magistrelli E; Rossi N; Rosselli Del Turco E; Bussini L; Borderi M; Viale P
    HIV Clin Trials; 2017 May; 18(3):110-117. PubMed ID: 28420298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study.
    Cesar C; Jenkins CA; Shepherd BE; Padgett D; Mejía F; Ribeiro SR; Cortes CP; Pape JW; Madero JS; Fink V; Sued O; McGowan C; Cahn P;
    Lancet HIV; 2015 Nov; 2(11):e492-500. PubMed ID: 26520929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The metabolic syndrome in HIV.
    Worm SW; Lundgren JD
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):479-86. PubMed ID: 21663841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study.
    Podlekareva DN; Efsen AM; Schultze A; Post FA; Skrahina AM; Panteleev A; Furrer H; Miller RF; Losso MH; Toibaro J; Miro JM; Vassilenko A; Girardi E; Bruyand M; Obel N; Lundgren JD; Mocroft A; Kirk O;
    Lancet HIV; 2016 Mar; 3(3):e120-31. PubMed ID: 26939735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children.
    Hazra R; Cohen RA; Gonin R; Monteiro JP; Hofer CB; Negra MD; Ruz NP;
    AIDS; 2012 Jan; 26(2):235-40. PubMed ID: 22008654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Features of Metabolic Syndrome and Its Associated Factors during Highly Active Antiretroviral Therapy in Ouagadougou (Burkina Faso).
    Guira O; Tiéno H; Diendéré AE; Sagna Y; Diallo I; Yaméogo B; Zoungrana L; Yaméogo TM; Bognounou R; Drabo JY
    J Int Assoc Provid AIDS Care; 2016; 15(2):159-63. PubMed ID: 26307211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome and cardiovascular risk in HIV-infected patients with lipodystrophy.
    Falasca K; Ucciferri C; Manzoli L; Mancino P; Pizzigallo E; Conti P; Vecchiet J
    Int J Immunopathol Pharmacol; 2007; 20(3):519-27. PubMed ID: 17880765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy.
    Vergis EN; Paterson DL; Wagener MM; Swindells S; Singh N
    Int J STD AIDS; 2001 Jul; 12(7):463-8. PubMed ID: 11394983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.